Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1504-1506

  Metcalfe, John Z ^a   Makumbirofa, Salome ^b   Makamure, Beauty ^b   Mutetwa, Reggie ^b   Peñaloza, Renée A ^a   Sandy, Charles ^c   Bara, Wilbert ^d   Mungofa, Stanley ^d   Hopewell, Philip C ^a   Mason, Peter ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BIOMEDICAL RESEARCH AND TRAINING INSTITUTE   (Zimbabwe)

^c National Tuberculosis Control Program   (Zimbabwe)

^d Harare City Health Department   (Zimbabwe)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; DIAGNOSTIC KIT;

ANTIBIOTIC RESISTANCE; BACTERIUM DETECTION; CULTURE TECHNIQUE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MICROSCOPIC OBSERVATION DRUG SUSCEPTIBILITY CULTURE; MYCOBACTERIAL GROWTH INDICATOR TUBE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RETREATMENT; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; AREA UNDER THE CURVE; COMMUNICABLE DISEASE CONTROL; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; MICROBIOLOGY; PROCEDURES; REPRODUCIBILITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AREA UNDER CURVE; COMMUNICABLE DISEASE CONTROL; FALSE POSITIVE REACTIONS; HUMANS; MASS SCREENING; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929017959     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00214114     Document Type: Letter

References (17)

1. World Health Organization. Global Tuberculosis Report 2014. Geneva, WHO Press, 2014. www.who.int/tb/publications/global-report/en/.
2. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.
3. Pantoja A, Fitzpatrick C, Vassall A, et al. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: A cost and affordability analysis. Eur Respir J 2013; 42: 708-720.
4. Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 1: CD009593.
5. Kennedy N, Gillespie SH, Saruni AO, et al. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. J Infect Dis 1994; 170: 713-716.
6. Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013; 1: 462-470.
7. Boyles TH, Hughes J, Cox V, et al. False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis 2014; 18: 876-878.
8. Kelly JD, Grace Lin SY, Barry PM, et al. Xpert MTB/RIF false detection of rifampin-resistant tuberculosis from prior infection. Am J Respir Crit Care Med 2014; 190: 1316-1318.
9. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
10. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 2011; 377: 1495-1505.
11. Nicol MP. Xpert MTB/RIF: monitoring response to tuberculosis treatment. Lancet Respir Med 2013; 1: 427-428.
12. World Health Organization. Noncommercial culture and drug-susceptibility testing methods for screening of patients at risk of multidrug resistant tuberculosis: policy statement. Geneva, WHO Press, 2011. http://whqlibdoc.who.int/publications/2011/9789241501620-eng.pdf.
13. Martin L, Coronel J, Faulx D, et al. A field evaluation of the Hardy TB MODS kit for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis. PLoS One 2014; 9: e107258.
14. Dorman SE, Chihota VN, Lewis JJ, et al. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS One 2012; 7: e43307.
15. Pencina MJ, D'Agostino RB, Pencina KM, et al. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012; 176: 473-481.
16. Rachow A, Zumla A, Heinrich N, et al. Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay - A clinical validation study. PLoS One 2011; 6: e20458.
17. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184: 132-140.